| 9/8/2010 |
Hemispherx Biopharma to Present at the Rodman and Renshaw 12th Annual Healthcare Conference
|
| 9/8/2010 |
HEMISPHERX BIOPHARMA TO PRESENT NEW RETROVIRUS (XMRV) DATA AT 1ST INTERNATIONAL WORKSHOP ON XMRV
AND CHRONIC FATIGUE SYNDROME (CFS)
…Retrovirus Positive CFS Patients Show Enhanced Response to Ampligen®, An Experimental Therapeutic, Relative to XMRV Negative Group
|
| 8/24/2010 |
HEMISPHERX SETTLES ALL SECURITIES CLASS ACTIONS Title
|
| 8/18/2010 |
Hemispherx Biopharma Awarded $188 Million Judgment against JCI
…Culmination of 6 Year Litigation Battle In U.S. Federal Courts
|
| 8/6/2010 |
HEMISPHERX BIOPHARMA, INC. 2nd QUARTER 2010 FINANCIAL RESULTS
…Drug / Biologic Development Progress in North America, India and Japan
|
| 7/19/2010 |
The Indian Drugs Controller General Approves Start of Clinical Study of Hemispherx Biopharma’s Natural Interferon Product, Alferon N Injection®, in Hospitalized Flu Patients
. . . Clinical Sites Expected to Enroll Subjects During Monsoon Season
|
| 7/15/2010 |
Hemispherx Publishes Full Report of Three Year Joint Research Program at Japanese NIID
…..Full Report Setting Stage for Clinical Testing of Novel Flu Vaccine/Ampligen® Combination Now Available on Hemispherx’s Website
|
| 7/12/2010 |
Hemispherx Reports Successful Culmination of Three Year Joint Research Program at Japanese NIID
…..Sets Stage for Clinical Testing of Novel Flu Vaccine/Ampligen® Combination.
|
| 6/15/2010 |
Hemispherx Biopharma Licenses Platform Technologies to GP Pharm
.…Initial Commercial Target is Chronic Fatigue Syndrome in Latin America
|
| 5/17/2010 |
Hemispherx Biopharma Prepares Application to Initiate Phase II
Clinical Trials in China with Ampligen®
. . . Proposed Trial to Address Seriously Ill Patients with Influenza
|
| 5/13/2010 |
Hemispherx Biopharma to Present at the Rodman Healthcare Conference
|
| 5/7/2010 |
HEMISPHERX BIOPHARMA, INC. 1st QUARTER 2010 FINANCIAL RESULTS
|
| 5/3/2010 |
New Independent Data Monitoring Committee Established by Hemispherx to Accelerate Global Drug Development
|
| 4/1/2010 |
Hemispherx Biopharma and Max Neeman International Team
Initiate Influenza Research Programs
. . . Clinical Sites Targeted to Enroll Subjects Beginning in Upcoming Monsoon Season
|
| 3/23/2010 |
Stanford University Researcher and Hemispherx Biopharma Consultant
Present New Integrative Immunotherapy Approach
……suggests that the safety and bioactivity of TLR3 agonists may be unique
|
| 3/15/2010 |
Hemispherx Biopharma Announces 2009 Financial Results
Cash and Cash Equivalent Increase 9 Fold over Prior Year
|
| 2/23/2010 |
Hemispherx Biopharma Acquires New Internet Domain Rights
...will provide new portals to access Ampligen®/Alferon® N information
|
| 2/11/2010 |
Hemispherx Announces Award of 2009 Executive Bonuses
|
| 2/8/2010 |
New Animal Model for Evaluating Antiviral Agents Against the SARS Virus
Indicates Potential Effect of Ampligen®, an Experimental Therapeutic
...Independent University Researchers Find Ampligen® “Fully Protective” in Study
|
| 2/4/2010 |
Hemispherx Biopharma Appoints Two Senior
Pharma Executives to Key Manufacturing Positions
|
| 2/2/2010 |
Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That The FDA Seattle District Accepts Ampligen® Manufacturing Response
|
| 1/28/2010 |
Stanford University Publishes New Data on Immuno-potential of
Hemispherx’s Ampligen®
….May Enhance Bioactivity of Cancer Immunotherapies
|
| 1/14/2010 |
Hemispherx Biopharma provides Grant to IACFS to assist in the Development of Chronic Fatigue Syndrome (CFS) Clinical Guidelines
|
| 1/14/2010 |
Hemispherx Biopharma Addresses Ampligen® CFS Preclinical Issues
|
| 12/16/2009 |
Hemispherx Biopharma Addresses Ampligen® Manufacturing Issues
|
| 12/2/2009 |
Hemispherx Biopharma Announces Investor Conference Call
|
| 12/1/2009 |
Hemispherx Biopharma Receives Complete Response Letter from FDA on Ampligen® New Drug Application for Chronic Fatigue Syndrome
…Outlines Additional Recommendations
|
| 11/16/2009 |
Class Action Lawsuit Against Hemispherx Biopharma Is Without Merit
|
| 11/9/2009 |
HEMISPHERX BIOPHARMA, INC. 3rd QUARTER 2009 FINANCIAL RESULTS
……Cash/Cash Equivalents Increase Almost 10 Fold And Net Loss For Quarter Reduced 29%
|
| 11/2/2009 |
Hemispherx Biopharma Updates Chronic Fatigue Syndrome (CFS)
Treatment and Commercial Application Programs
......Targets Completion of All NDA Regulatory Responses and
Initiation of Expanded Clinical Collaborations in CFS
|
| 10/26/2009 |
Japanese NIH Expands Pandemic Flu Protective Potential by Ampligen®
......New Publication Suggests Pandemic Vaccines Adjuvanted are More Effective; The Potential Importance of Antigen Sparing and Cross-Protective Formulations
|
| 10/15/2009 |
Japanese NIH Research Reaffirms and Expands Pandemic Flu Protection by Ampligen®
......New Data at recent “Mucosal Immunity” International Workshop in Osaka Suggest Alternative Method to Protect at High Risk Groups
|
| 10/13/2009 |
New Infectious Retrovirus Detected in Chronic Fatigue Syndrome
….May Clarify Mechanism of Action of Hemispherx’s Ampligen®
|
| 10/8/2009 |
Hemispherx’s Ampligen®/ Intranasal Flu Vaccine Program to be Presented at International Vaccine Workshop in Osaka
….Coincides with First Deliveries of Intranasal Pandemic Vaccine in
U.S. to High Risk Groups
|
| 10/2/2009 |
Stanford University Presents New Data on Immuno-potential of
Hemispherx’s Ampligen®
….May Enhance Bioactivity of Cancer Immunotherapies
|
| 9/24/2009 |
Japanese National Institute of Health to Present New Data on Hemispherx’s Vaccine Enhancer
....Emphasis on Prevention of Pandemic Influenza
|
| 9/23/2009 |
Hemispherx Presents at the Maxim Group Annual Growth Conference
....Emphasis on Prevention, Prophylaxis and Treatment of Influenza
|
| 9/16/2009 |
Hemispherx Board of Directors Authorizes Multimillion Dollar Expansion of its FDA Licensed Manufacturing Facilities
....Increases Capability to Expand Alferon LDOTM and Ampligen® for
Various Influenza-Based Clinical and Commercial Production
|
| 9/2/2009 |
Hemispherx Biopharma Presents at the Rodman Healthcare Conference
....New Comparative Analysis on Alferon LDO in Pandemic Influenza
|
| 9/2/2009 |
Hemispherx Biopharma Announces Cancellation of Adjourned Stockholders’ Meeting
|
| 8/10/2009 |
HEMISPHERX BIOPHARMA, INC. 2nd QUARTER 2009 FINANCIAL RESULTS
Cash Position Increases Approximately 6.5 Fold and Influenza Studies Expand
|
| 7/22/2009 |
Hemispherx Biopharma Announces Further Adjournment on Proposal Number 3 from the 2009 Annual Meeting of Stockholders
|
| 7/20/2009 |
HEMISPHERX BIOPHARMA TO PROVIDE UPDATE ON GLOBAL PANDEMIC
INFLUENZA PREVENTION / TREATMENT INITIATIVES
|
| 6/24/2009 |
Hemispherx Biopharma Reports on Annual Stockholder Meeting
|
| 6/17/2009 |
Hemispherx Biopharma appoints Robert Dickey IV to the new position of Senior Vice President
Role to facilitate strategic partnering and clinical progress
|
| 6/16/2009 |
Hemispherx Biopharma Provides Corporate Update on Various Strategic Initiatives
|
| 6/12/2009 |
Hemispherx’s Collaborative Partner in Japan, Biken Corp., Expands Production Capacity for Swine/Avian Flu Vaccines
…WHO Raises Threat of Swine Flu to Pandemic Level
|
| 6/4/2009 |
Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma’s Drug Technology as the “Most Promising Mucosal Adjuvant for Influenza”
.....Topical Application Also Affords Strong Cross-Protection against Variant Flu Strains
|
| 6/1/2009 |
Hemispherx Biopharma Presents Influenza Prevention / Treatment Platform at International Conference in Rome under Auspices of Italian Government
….Company Accelerates Collaborations with Governmental, Academic and Pharmaceutical Groups to Prevent Pandemic Influenza
|
| 5/27/2009 |
Hemispherx Announces Payment of 2008 Executive Bonuses
|
| 5/26/2009 |
HEMISPHERX BIOPHARMA ANNOUNCES POSSIBLE BRIEF DELAY IN FDA ACTION ON AMPLIGEN® NEW DRUG APPLICATION
|
| 5/21/2009 |
Japan’s Council Awards Innovative Technology Grants for Pandemic Influenza Vaccines Adjuvanted by Hemispherx’s Ampligen®
…“Super Special Consortia” to promote key technologies
|
| 5/19/2009 |
Hemispherx Biopharma Announces $16 Million Public Equity Offering
|
| 5/12/2009 |
HEMISPHERX BIOPHARMA, INC. 1st QUARTER 2009 FINANCIAL RESULTS
Operating Cash Requirements Reduced 49%
|
| 5/11/2009 |
Hemispherx Biopharma Announces $18.3 Million Public Equity Offerings
|
| 4/27/2009 |
Japanese Government Accelerates Hemispherx Biopharma’s Ampligen® Research Programs for Influenza Protection
…..Flu Virus Mutations May Limit Tamiflu Usefulness
|
| 3/17/2009 |
HEMISPHERX BIOPHARMA, INC. TO DISCUSS NEW CHRONIC FATIGUE SYNDROME CLINICAL DATA AND YEAR-END 2008 RESULTS ON MARCH 19, 2009
|
| 3/16/2009 |
HEMISPHERX BIOPHARMA, INC. ANNOUNCES 2008 FINANCIAL RESULTS
Multiple Commercial- Directed Programs Progress; Net loss Reduced 31%
|
| 2/18/2009 |
HEMISPHERX BIOPHARMA TO PRESENT NEW AMPLIGEN® CLINICAL DATA AT THE 9TH INTERNATIONAL IACFS/ME CONFERENCE
Clinical/lab Parameters of Potential Special Import to CFS Disease Severity
|
| 2/18/2009 |
FDA EXTENDS HEMISPHERX’S NDA REVIEW DATE FOR AMPLIGEN® AS POTENTIAL TREATMENT FOR CFS
Extended User Fee Goal is now May 25, 2009
|
| 1/5/2009 |
U.S. Court of Appeals Supports Hemispherx in Rebuff of
Hostile Takeover Attempt
|
| 12/4/2008 |
Hemispherx Biopharma Announces New Chief Financial Officer
|
| 11/28/2008 |
ATTORNEY THOMAS EQUELS ELECTED TO HEMISPHERX BIOPHARMA
BOARD OF DIRECTORS
|
| 11/28/2008 |
Hemispherx Biopharma Introduces Expense Reduction Program
……Medical, Regulatory, Manufacturing Operations Remain Intact
|
| 11/18/2008 |
Hemispherx Enters Major Contract with Lovelace Respiratory Institute
…..Projected New Data to Enhance Ampligen® NDA Filing Status in
Chronic Fatigue Syndrome
|
| 11/10/2008 |
HEMISPHERX BIOPHARMA, INC. RELEASES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2008
….Net Loss Reduced 40% over Prior Year
|
| 10/28/2008 |
Hemispherx Selected to Present at 7th Annual BIO Investor Forum
…..Showcases Leading Growth Companies in Life Sciences
|
| 10/28/2008 |
Hemispherx Selected to Present at 7th Annual BIO Investor Forum
…..Showcases Leading Growth Companies in Life Sciences
|
| 10/27/2008 |
Immune Adjuvants and Cancer Vaccines: Hemispherx’s New Enhancement Strategy
…….To be Unveiled at Upcoming 23rd Annual Biotherapy Conference
|
| 10/23/2008 |
Nobel Laureate Confirms Importance of Adjuvants in Controlling Devastating Diseases
……Hemispherx’s Adjuvant Portfolio among the Most Studied at Clinical Level
|
| 10/21/2008 |
HEMISPHERX BIOPHARMA TO PRESENT AT 48th ANNUAL ICAAC CONFERENCE
…Presentation Highlights Pending NDA Data for Treating CFS
|
| 10/17/2008 |
HEMISPHERX BIOPHARMA, INC. ADJOURNS STOCKHOLDER MEETING
TO NOVEMBER 11, 2008
|
| 10/9/2008 |
HEMISPHERX SCIENTIFIC ADVISORY BOARD MEMBER, DR. LUC MONTAGNIER, RECEIVES NOBEL PRIZE FOR MEDICINE
Director of the World Foundation for AIDS Research and Prevention Advocates Investigation of Widespread Use of Alferon LDO to Combat Life-Threatening Viral Infections
|
| 10/6/2008 |
HEMISPHERX ENGAGES THE SAGE GROUP
AS ITS CORPORATE PARTNERSHIP ADVISOR FOR AMPLIGEN®
TO TREAT CHRONIC FATIGUE SYNDROME
|
| 9/30/2008 |
HEMISPHERX TO PRESENT DATA AT “SECOND WORLD CONFERENCE ON MAGIC BULLETS (ERLICH II)”
|
| 9/23/2008 |
JAPANESE NIH SCIENTISTS REPORT ROBUST CROSS-PROTECTION WITH HEMISPHERX DRUG AGAINST MULTIPLE STRAINS OF BIRD FLU
. . . Findings Coincide with Newly Reported Bird Flu Epidemic in
Northern Japanese Swans.
|
| 9/17/2008 |
HEMISPHERX BIOPHARMA, INC. ADJOURNS STOCKHOLDER MEETING DUE TO LACK OF A QUORUM TO OCTOBER 17, 2008
|
| 9/3/2008 |
HEMISPHERX BIOPHARMA TO PRESENT AT BIOPHARM AMERICA CONFERENCE …Accelerates Commercial Focus with Multiple Registration Targets, Including Vaccine Enhancement
|
| 8/12/2008 |
HEMISPHERX BIOPHARMA, INC. RELEASES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2008
. . . Programs Accelerate in United States, Japan and Australia
|
| 7/15/2008 |
HEMISPHERX BIOPHARMA TO HOST INVESTOR CONFERENCE CALL
ON CHRONIC FATIGUE SYNDROME NDA FILING
Discussion to also address other corporate initiatives
|
| 7/14/2008 |
Hemispherx Biopharma, Inc. Announces Settlement
of All Bioclones/Ribotech Litigation
Discussions in progress for potential future partnership in HIV/AIDS and Hepatitis
|
| 7/8/2008 |
Hemispherx Biopharma’s Ampligen® NDA for Chronic Fatigue Syndrome Accepted for Review by the FDA
Marks the first drug candidate for approval to treat CFS,
and the first compound in the TLR class
|
| 6/16/2008 |
Hemispherx Biopharma, Inc. Announces Settlement of
Arbitration with Laboratorios del Dr. Esteve
Hemispherx regains licensing rights in Spain, Portugal and Andorra
|
| 6/2/2008 |
Hemispherx Biopharma, Inc. Completes Enrollment in Phase II Study
of Ampligen® as Seasonal Flu Vaccine Enhancer
Six-month study will also assess potential cross-protection against H5N1 avian influenza
|
| 5/13/2008 |
HEMISPHERX BIOPHARMA, INC. RELEASES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2008
….Losses reduced by 38% over prior 2007 period; Progress made with Three Platform Technologies
|
| 4/7/2008 |
HEMISPHERX BIOPHARMA
TO HOST INVESTOR CONFERENCE CALL
Discussion to focus on Year-end 2007 Financials, Chronic Fatigue Syndrome NDA Update, and Corporate Initiatives for 2008
|
| 4/7/2008 |
HEMISPHERX BIOPHARMA, INC. ACCELERATES
AMPLIGEN® AS A POTENTIAL ADJUVANT FOR BOTH
AVIAN INFLUENZA AND HIV VACCINES
New Approach Produces Robust Immunity to Overcome Therapeutic Obstacles
|
| 3/18/2008 |
HEMISPHERX BIOPHARMA, INC. ANNOUNCES 2007 FINANCIAL RESULTS
………Net loss decreases over year 2006
|
| 3/6/2008 |
HEMISPHERX BIOPHARMA REACHES AGREEMENT WITH FDA ON SPECIFIC STEPS TO ACHIEVE COMPLETE NDA ON PROPOSED CFS TREATMENT
… No Additional Studies Indicated
|
| 2/26/2008 |
Hemispherx Biopharma to Present at Jesup & Lamont Conference
|
| 2/11/2008 |
Hemispherx Biopharma to Present at New York Bio Conference
|
| 1/9/2008 |
Hemispherx Biopharma Addresses FDA Questions On Ampligen NDA
First 'TLR' Drug Candidate for Systemic Use
|
| 12/27/2007 |
Hemispherx Announces Executive Bonuses
|
| 12/27/2007 |
Hemispherx’s CFS Clinical Programs Reviewed in European Community
United Kingdom report focuses on Chronic Fatigue Syndrome and Ampligen®, an experimental therapeutic
|
| 12/19/2007 |
Hemispherx Biopharma Comments on 2005 BDO Audit News
BDO Internal Deficiencies Did Not Involve Hemispherx Personnel and Financial Statements Improved upon Reissuance
|
| 12/17/2007 |
HEMISPHERX BIOPHARMA ANNOUNCES INVESTORS CONFERENCE CALL
Discussion to focus on Vaccine Licensing agreements and updates on CFS filing status
|
| 12/13/2007 |
HEMISPHERX BIOPHARMA ANNOUNCES LICENSING/ RESEARCH AGREEMENTS ON AMPLIGEN® AS INFLUENZA ADJUVANT WITH JAPAN’S BIKEN
FACILITATES BIRD FLU VACCINE DEVELOPMENT FUNDED BY JAPANESE GOVERNMENT
|
| 12/10/2007 |
HEMISPHERX BIOPHARMA INTENDS TO TERMINATE LICENSE TO ESTEVE FOR THE MARKETING OF AMPIGEN® FOR CHRONIC FATIGUE SYNDROME (CFS) IN CERTAIN TERRITORIES
Company Expects to Regain Marketing Rights in Spain, Portugal and Andorra
|
| 12/8/2007 |
HEMISPHERX BIOPHARMA
ANNOUNCES INVESTORS CONFERENCE CALL
Discussion to focus on NDA Filing Status
|
| 12/7/2007 |
HEMISPHERX BIOPHARMA RECEIVES NOTICE OF
INCOMPLETE NEW DRUG APPLICATION (NDA)
Company Expects to Respond Promptly while Moving Forward
on Planned Filings outside the U.S.
|
| 12/6/2007 |
Hemispherx Biopharma to Present at the NYSSA
11th Annual Biotech/Specialty Pharma Conference
Updates Provided on Global Initiatives
|
| 11/29/2007 |
HEMISPHERX BIOPHARMA ANNOUNCES CHANGE IN AUDIT COMMITTEE
|
| 11/12/2007 |
Japan Institute of Infectious Diseases Publishes Second Article on Ampligen® as Avian Flu Vaccine Immune Enhancer
Data Supports Potential Extension of H5N1 Vaccine Supplies by Means of Co-Administration with Hemispherx Biopharma’s Ampligen®
|
| 11/8/2007 |
HEMISPHERX BIOPHARMA
ANNOUNCES INTERIM FINANCIAL RESULTS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2007
With Debt Retired in July and NDA for Ampligen® to Treat CFS Filed in October, Focus is On Anticipated Drug Development Milestones
|
| 10/31/2007 |
HEMISPHERX BIOPHARMA PRESENTS AT
RODMAN & RENSHAW 9th ANNUAL HEALTHCARE CONFERENCE
Expands on Commercialization progress with TLR3 based Therapeutics
|
| 10/18/2007 |
Japan Institute of Infectious Diseases Publishes Article on Ampligen® as Avian Flu Vaccine Immune Enhancer
Hemispherx Biopharma’s Ampligen® Plus Seasonal Influenza Vaccine Yields Encouraging Data on Pandemic Potential Control
|
| 10/11/2007 |
Hemispherx Biopharma Files New Drug Application for Ampligen®
as Treatment of Chronic Fatigue Syndrome
NDA of investigational drug includes four well-controlled trials,
more than 1,200 trial subjects and 90,000 doses
|
| 9/10/2007 |
Japan’s National Institute of Infectious Diseases Widens Research on Hemispherx’s Ampligen®, An Immune Enhancer, Co-Administered with a Vaccine in AIDS Research
Intranasal Vaccination for HIV-1 Utilizing Ampligen® as an Immuno Enhancer Holds Promise
|
| 8/27/2007 |
Hemispherx Biopharma Accelerates Enrollment in West Nile Virus Controlled Trial of Alferon N™ as Cases Increase Nationwide
• Also Announces Increase in Revenues from Alferon N Injection® HPV Indication Under Armada Specialty Pharmacy Agreement
|
| 7/2/2007 |
Hemispherx Biopharma Retires All Outstanding Debentures
|
| 6/26/2007 |
Hemispherx Biopharma Initiates Phase IIb Trial in Australia for Ampligen as Vaccine Adjuvant for Seasonal Influenza
…Goal is to Evaluate Immune Augmentation and Possible Cross-Protection by TLR Ligand Ampligen®
|
| 5/31/2007 |
Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference
Alferon-LDO Primate Results Suggest Potential to Treat Healthcare Workers and “First Responders” in HPAI Outbreak
|
| 5/22/2007 |
Hemispherx to Present New Therapeutic Results at Paris Anti-Avian Influenza Conference
Existing therapy may be significantly improved; pneumonia may be mitigated.
|
| 5/11/2007 |
HEMISPHERX BIOPHARMA ANNOUNCES
FIRST QUARTER 2007 FINANCIAL RESULTS
Quarterly Loss Decreases as Cash Reserves Increase
|
| 5/10/2007 |
HEMISPHERX BIOPHARMA TO PRESENT AT RODMAN & RENSHAW
4th ANNUAL GLOBAL HEALTHCARE CONFERENCE
|
| 4/30/2007 |
New Report Illuminates Ampligen®’s Unique Mechanism of Action
Hemispherx Biopharma’s Proprietary Experimental Therapeutic Activates TLR-3 Receptor to Potentiate Broad-Spectrum Immune Response
|
| 4/23/2007 |
Hemispherx and Armada Health Care enter Agreement to Launch Alferon N Injection® via Specialty Pharmacy Network
Utilizing SP Capabilities to Facilitate Expanded Access to Biotech Drugs
|
| 4/19/2007 |
HEMISPHERX BIOPHARMA
ANNOUNCES INVESTORS CONFERENCE CALL
Discussion to focus on Year-end 2006 Financials, CFS NDA Program Update, the Japan initiative and New Strategic Directions
|
| 4/12/2007 |
Japanese Ministry Awards Grant to advance studies with Influenza Vaccines co-administered with Hemispherx’s Ampligen®
Studies indicate Ampligen’s® ability to increase efficacy of Influenza Vaccines across various strains
|
| 3/19/2007 |
HEMISPHERX BIOPHARMA
ANNOUNCES 2006 FINANCIAL RESULTS
….Infrastructure and Financial Resources Increase as Potential Commercial Opportunities Emerge
|
| 2/14/2007 |
Hemispherx Avian Flu Prevention/Treatment Program Announces New Primate Results and Expands in both Europe and Southern Hemisphere
Experimental Treatment Designed to Prevent/Treat Multiple H5N1 Classes with Oral Non-Toxic Treatment
|
| 1/23/2007 |
Hemispherx Biopharma to Present at The Roth Capital Partners
19th OC Conference in Dana Point, California
|
| 12/12/2006 |
Hemispherx Comments on Chronic Fatigue Syndrome Initiatives by the Centers for Disease Control
|
| 11/28/2006 |
Hemispherx Biopharma Hires New President/Chief Operating Officer to Lead the Company’s Drive to Commercialization
|
| 11/9/2006 |
Hemispherx Biopharma Appoints McGladrey & Pullen as Independent Auditing Firm
|
| 11/6/2006 |
HEMISPHERX BIOPHARMA ANNOUNCES
THIRD QUARTER 2006 RESULTS AND STRATEGIC UPDATE
•Strategic update conference call and webcast scheduled for Wednesday, November 15, 2006 on RNA based therapeutics.
|
| 10/30/2006 |
Hemispherx Biopharma to Present at Rodman & Renshaw Healthcare Conference, November 6th
Emphasis Placed on Advances with Chronic Fatigue Syndrome
|
| 10/23/2006 |
Researchers at Japanese National Institute of Infectious Diseases Present New Data on Hemispherx’s Vaccine Enhancement Platform
First Demonstration that Intranasal Administration of Ampligen®, Combined with H5N1 Vaccine, Will Induce Broad Cross-Protective Mucosal Immunity
|
| 10/19/2006 |
Hemispherx Biopharma Will Present at Urchin Capital Partners
“Value Below the Radar 2006” Investor Conference
on October 24, 2006 in San Francisco
|
| 10/16/2006 |
Hemispherx Biopharma’s Vaccine Enhancement Platform to be Presented at the Second International Conference on Influenza Vaccines for the World
Researchers at Japanese National Institute of Infectious Diseases to Present New Data
|
| 9/21/2006 |
HEMISPHERX BIOPHARMA TO PRESENT AT 8TH INTERNATIONAL IACFS CONFERENCE ON CHRONIC FATIGUE SYNDROME, FIBROMYALGIA, RELATED ILLNESSES
Successful Transfer of Technology to Expand Drug Production Announced
|
| 9/18/2006 |
HEMISPHERX BIOPHARMA TO PRESENT AT
Fall 2006 Micro Cap Conference
|
| 8/29/2006 |
Hemispherx Biopharma Acquires New Technology to Advance
DNA-Based Vaccine Production
|
| 8/16/2006 |
HEMISPHERX BIOPHARMA TO HOST QUARTELY CONFERENCE CALL
Management to provide update on status of Active NDA Preparation and Avian Influenza Programs
|
| 8/14/2006 |
HEMISPHERX BIOPHARMA SECOND QUARTER 2006 EARNINGS ANNOUNCED
Cash and Cash Equivalents Increased $5.3 Million for Six Months ended June 30, 2006
|
| 8/1/2006 |
Hemispherx Biopharma Announces Purchase of Royalty Interest from Stem Cell Innovations, Inc.
Only Natural Alpha Interferon Product on the U.S. Market
|
| 7/27/2006 |
Hemispherx Biopharma Wins AMEX Compliance Approval,
Looks Ahead to Promising Pharmaceutical Line-Up
|
| 7/6/2006 |
Science News Cover Story Highlights Hemispherx Biopharma in
New Insights Confronting Chronic Fatigue Syndrome
Promising Experimental Medicine is Designated First Specific Drug Candidate for CFS
|
| 6/30/2006 |
HEMISPHERX BIOPHARMA
FIRST QUARTER 2006 EARNINGS ANNOUNCED
|
| 6/27/2006 |
Hemispherx Biopharma to Present at the
The First International Conference on Avian Influenza in Humans
At the Pasteur Institute
Novel Therapeutic Approach Attacks Virus at 3 Levels Simultaneously
|
| 6/15/2006 |
HEMISPHERX BIOPHARMA TO PRESENT AT THE RODMAN & RENSHAW 3RD ANNUAL SECURITY, BIODEFENSE & CONNECTIVITY INVESTOR CONFERENCE
Company’s Biodefense Shield and Avian Influenza Program Highlighted
|
| 6/12/2006 |
Hemispherx Biopharma Advances Influenza Vaccine/Immunopotentiation Clinical Trials Designed to Increase Vaccine Dosage Supply and Increase Cross-Protection
Australian Clinical Protocol Complete
|
| 6/5/2006 |
HEMISPHERX BIOPHARMA Files Amended 10-K for 2005 and Announces Restatement of Financials for 2003 and 2004
Impact to Statement of Operations is an Increase in Net Loss Applicable to Common Stockholders of $.01 per share in 2003 and a Decrease of $0.07 in 2004 for an Accumulative Net Decrease in Loss Applicable to Common Stockholders of $2,777,000 for these Periods
|
| 5/15/2006 |
Hemispherx Biopharma Announces Influenza Vaccine/Immunopotentiation Clinical Trials Designed to Increase Vaccine Dosage Supply and Increase Cross-Protection
|
| 5/12/2006 |
Hemispherx Announces Approval by AMEX of Plan to Achieve Compliance Status
|
| 5/3/2006 |
Hemispherx Biopharma to Present Audited Results of Ampligen® Clinical Trials on Chronic Fatigue Syndrome at 5th International Conference on HHV; Studies Show Medically Significant Improvements Among CFS Patients
|
| 4/25/2006 |
Hemispherx Biopharma Announces Retention of New Senior Personnel and Contractors Ahead of Key NDA Filing for Chronic Fatigue Syndrome Treatment
New Management and R&D Team to Build on Critical Research on CFS Just Unveiled by Centers for Disease Control
|
| 4/13/2006 |
Letter to Shareholders of Hemispherx Biopharma, Inc. from William A. Carter, M.D., Chairman of the Board and Chief Executive Officer
|
| 4/11/2006 |
HEMISPHERX BIOPHARMA TO HOST CONFERENCE CALL TO REVIEW COMPANY’S ACCOMPLISHMENTS, UPDATE ON INFLUENZA RELATED STUDIES AND OUTLINE FUTURE GOALS
|
| 4/7/2006 |
Hemispherx Biopharma, Inc. Late Filing of Form 10-K Generates Standard Non-Compliance Notification From The AMEX
|
| 4/3/2006 |
Hemispherx Biopharma, Inc. Announces Delay in Filing Its Form 10-K for the Fiscal Year Ended December 31, 2005
|
| 3/16/2006 |
New Research From Hemispherx Biopharma Leverages Recent Studies to Identify Factors in Breakdown of Immune System; May Help Prevent Spread of Avian Flu
Results to be presented at the VIII International Symposium on Respiratory Viral Infections March 16-19 in Hawaii
Japanese researchers initiate primate studies with co-administration of Hemispherx Biopharma’s Ampligen and H5N1 vaccine
|
| 2/16/2006 |
3 New Studies Show Hemispherx Biopharma’s Ampligen® and Alferon® LDO May Provide Defense Against Avian Flu
Tests Indicate Potential of Ampligen® As Vaccine Adjuvant, Boosts Existing Drugs Tamiflu®, Relenza® Up To 100 Times; Alferon® LDO Found to Stimulate Production of Interferon, Offering Natural Defense Against Virus
Consortium of Researchers to Present Findings at Today’s ASM Biodefense Research Meeting in Washington, D.C.
|
| 1/3/2006 |
HEMISPHERX BIOPHARMA LETTER TO SHAREHOLDERS
|
| 12/20/2005 |
Hemispherx to Present at the 4th Annual Biodefense Research Meeting Sponsored by the American Society of Microbiology,
Ampligen® and Alferon® in Global Clinical / Animal Trials Against Avian Influenza
|
| 12/13/2005 |
Hemispherx Highlighted in Study of Innate Immunity
As a Defense Against Bio-terror Threats,
Ampligen® and Alferon® featured in the December 2005 Journal of Allergy and Clinical Immunology
|
| 12/12/2005 |
HEMISPHERX BIOPHARMA TO PRESENT AT THE NEW YORK SOCIETY
OF SECURITY ANALYSTS 9TH ANNUAL HEALTHCARE
INDUSTRY CONFERENCE
New Influenza Treatment / Prevention Initiatives Introduced
|
| 11/29/2005 |
Hemispherx Biopharma Enters Research Agreement with Defence R&D Canada
Efficacy Evaluation of Ampligen® and Alferon® for the Prophylaxis of Human Respiratory Influenza Virus Infection
|
| 11/8/2005 |
HEMISPHERX BIOPHARMA
THIRD QUARTER 2005 EARNINGS ANNOUNCED
…. Net Loss Decreases 59% in Current Quarter
|
| 11/4/2005 |
Ampligen® Currently Administered to 750 “Very Ill” Patients Annually
|
| 11/3/2005 |
Studies Continue to Highlight Hemispherx’s Ampligen® as Broadly Effective Adjuvant to Avian Influenza Treatments
Ampligen® Demonstrates Strong Therapeutic Synergy with Relenza®
|
| 10/26/2005 |
Ampligen® Studies on Combinational Treatments Against Avian Influenza are Extended
Tamiflu Resistant Strains are Reported in Asia
|
| 10/10/2005 |
Hemispherx Biopharma signs Letter of Intent with HollisterStier Laboratories LLC
for the Production of Ampligen®
|
| 10/3/2005 |
Hemispherx Biopharma Signs Research Agreement with Japanese National Institute of Infectious Disease
Ampligen® sought as adjuvant for nasal flu vaccine
|
| 9/6/2005 |
Ampligen ® Enhances the Effectiveness of Tamiflu Against Avian Influenza
Second Independent Preclinical Study Confirms dsRNA Increases Flu Vaccine Effectiveness
|
| 9/1/2005 |
Hemispherx Biopharma Expands Manufacturing Facility for Production of Ampligen ®
Status of clinical Trial advancements for Alferon LDO and manufacturing programs updated in stockholder letter
|
| 8/10/2005 |
HEMISPHERX BIOPHARMA SECOND QUARTER 2005 EARNINGS ANNOUNCED
…. Net Loss Decreases By 36% in Current Quarter
|
| 7/6/2005 |
New Government Sponsored Research Points to Gene Malfunction
in Chronic Fatigue Syndrome (CFS)
....Exercise Induced Malfunction in Genes Provides New Potential Insight into Mechanism of Ampligen® Phase III Clinicals; Exercise Treadmill Improvement as Primary Efficacy Endpoint
|
| 5/16/2005 |
Alferon LDO Now in Human Clinical Trials As Experimental Antiviral/Immunodulatory Therapy
…. Accelerated evaluation of a synergistic cocktail of eight different alpha-interferons to potentially trigger “guardian angel” genes
|
| 5/16/2005 |
Alferon LDO Now in Human Clinical Trials As Experimental Antiviral/Immunodulatory Therapy
… Accelerated evaluation of a synergistic cocktail of eight different alpha-interferons to potentially trigger “guardian angel” genes
|
| 5/11/2005 |
HEMISPHERX BIOPHARMA
FIRST QUARTER 2005 EARNINGS ANNOUNCED
…. Net Loss Decreases By 62% in Current Quarter
|
| 5/3/2005 |
Chronic Fatigue Syndrome Presented at Symposium in New York
|
| 4/11/2005 |
Hemispherx Biopharma’s Investigational Drug Increases Physical Performance in New Chronic Fatigue Syndrome (CFS) Clinical Study
Maximum oxygen consumption increased 10-fold with Ampligen® vs. Placebo
|
| 3/30/2005 |
Hemispherx Biopharma to Present New Phase III Results in Chronic Fatigue Syndrome Treatment at 18th International Conference on Antiviral Research
|
| 3/21/2005 |
Hemispherx Biopharma Inc. Appoints Steven D. Spence to the Board of Directors
Former Managing Director of Merrill Lynch appointed to Executive and Audit Committees
|
| 2/24/2005 |
Hemispherx Biopharma’s Alferon N® Highlighted as Potential New Therapy for Avian Influenza on CNBC’s “Closing Bell”
“Battling the Bird Flu” Segment Features Microcap Company as Contender in the Avian Flu Drug Manufacturing Race
|
| 2/14/2005 |
HEMISPHERX BIOPHARMA, INC. ELECTS PRESIDENT AND CHIEF OPERATING OFFICER
…Experienced Executive in Business Development of Biopharmaceuticals
|
| 2/7/2005 |
HEMISPHERX BIOPHARMA EXPANDS EVALUATION OF ALFERON N AGAINST AVIAN FLU
Promising Effects In Bird Populations To Be Expanded based on WHO/UN Findings
….New Goal is Slow Disease, Minimize Risks; Eradication Looks Unlikely.
|
| 1/3/2005 |
HEMISPHERX BIOPHARMA INITIATES ENROLLMENT IN HIV/HEP-C CLINICAL PROGRAM
Clinical Trial with Ampligen In Collaboration With Esteve Laboratorios Targets HIV/HEP-C Twin Epidemics
|
| 12/27/2004 |
HEMISPHERX BIOPHARMA FILES LAWSUIT IN FEDERAL COURT ALLEGING CONSPIRACY BY FOREIGN NATIONALS TO MANIPULATE ITS STOCK PRICE AND ENGAGE IN ILLEGAL HOSTILE TAKEOVER
Members of conspiracy group already under criminal
investigation for stock fraud outside United States
|
| 12/21/2004 |
Los Angeles Times Article Focuses on Hemispherx Biopharma’s Experimental Drug Ampligen as a Potential New Therapy for Chronic Fatigue Syndrome
Prominent Experts on Chronic Fatigue Syndrome Comment in Article
|
| 11/22/2004 |
HEMISPHERX BIOPHARMA INITIATES ALFERON LDO® CLINICAL PROGRAM IN COLLABORATION WITH PRINCESS MARGARET HOSPITAL IN HONG KONG
Experimental Effort to Prevent Sudden Spread of Dreaded Viruses
in Large, At Risk Populations
|
| 11/12/2004 |
HEMISPHERX BIOPHARMA
THIRD QUARTER 2004 EARNINGS ANNOUNCED
…….Total Stockholders’ Equity Increases Approximately 146% in First 9 Months
|
| 11/8/2004 |
HEMISPHERX BIOPHARMA TO PRESENT AT THE NEW YORK SOCIETY
OF SECURITY ANALYSTS 8TH ANNUAL HEALTHCARE
INDUSTRY CONFERENCE
|
| 11/1/2004 |
Hemispherx Biopharma Presented New Data at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
in Washington, D.C.
|
| 10/25/2004 |
HEMISPHERX BIOPHARMA TO PRESENT AT THE RODMAN & RENSHAW TECHVEST 6TH ANNUAL HEALTHCARE CONFERENCE ON OCTOBER 27th
|
| 10/20/2004 |
Unexpected Neurological Damage Spreads with West Nile Virus;
Heightens Concern in Healthcare Community
• Hemispherix Biopharma Actively Enrolling Patients in the Only Existing National Clinical Trial of a New Therapeutic Agent
|
| 10/18/2004 |
Hemispherx Biopharma Comments on Recent Release of Data on Primary Endpoint in Phase III Chronic Fatigue Syndrome Study
•Treadmill Improvement is Standard for Evaluating Chronic Fatigue Syndrome and other Disabling Conditions
•Ampligen® Results Achieved Over Twice the Minimum Improvement Considered Medically Significant
|
| 10/11/2004 |
HEMISPHERX BIOPHARMA PRESENTS NEWPHASE III DATA ON AMPLIGEN® AT THE 7th INTERNATIONAL CONFERENCE
FOR CHRONIC FATIGUE SYNDROME
Treadmill Improvement Data Exceeds Initial Indications; Patients Receiving Ampligen Perform at Twice the Level
Historically Considered Medically Significant In Chronic Diseases
|
| 9/27/2004 |
Hemispherx Biopharma to Present New Data on Activity of Ampligen in Treating Chronic Fatigue Syndrome at Annual CFS Conference
Compares Activity of Ampligen(R) to Alzheimer Drug for Potential Treatment
|
| 9/9/2004 |
Griffin Securities Initiates Research Coverage of Hemispherx Biopharma With Buy Rating
|
| 9/7/2004 |
HEMISPHERX BIOPHARMA REPORTS COMMENCEMENT OF
TREATMENT OF WNV
|
| 8/10/2004 |
HEMISPHERX BIOPHARMA
SECOND QUARTER 2004 EARNINGS ANNOUNCED
Cash Position and the Total Shareholders’ Equity Increased
|
| 8/6/2004 |
HEMISPHERX BIOPHARMA, INC. ANNOUNCES COMPLETION OF PRIVATE PLACEMENT
|
| 8/5/2004 |
Hemispherx Biopharma To Announce Second Quarter Financial Results and to Update Clinical Activities on Wednesday, August 11th
Company to Hold Conference Call and Webcast for Investors at 9 a.m. that day
|
| 8/2/2004 |
HEMISPHERX BIOPHARMA ANNOUNCES PRIVATE PLACEMENT OF COMMON STOCK AND WARRANTS
|
| 8/2/2004 |
HEMISPHERX BIOPHARMA TO REPORT NEW DATA ON PIVOTAL PHASE III STUDY IN CFS
…..Hemispherx Expands Pivotal Study Results at Upcoming 44th ICAAC Meeting
|
| 7/21/2004 |
HEMISPHERX BIOPHARMA REPORTS ON WEST NILE VIRUS
. . . Alferon-N Well-Controlled Clinical Trial Accelerates by New Human Cases
of WNV Now Reported in Twelve States
|
| 7/20/2004 |
HEMISPHERX BIOPHARMA RECEIVES FDA AUTHORIZATION FOR CLINICAL TRIAL IN MULTIPLE SCLEROSIS
Trial Approved for Patients in Resistant / Intolerant MS Group
|
| 7/7/2004 |
HEMISPHERX BIOPHARMA INITIATES HIV/HEP-C CLINICAL PROGRAM
Clinical Trial with Ampligen In Collaboration With Esteve Laboratorios Targets HIV/HEP-C Twin Epidemics
|
| 6/24/2004 |
HEMISPHERX BIOPHARMA COMPLETES CORPORATE GOVERNANCE CERTIFICATION
Company Fully Complies with the AMEX Corporate Governance Requirements
|
| 6/14/2004 |
HEMISPHERX BIOPHARMA LAUNCHES MULTIPLE SCLEROSIS
SALVAGE PROGRAM WITH NATURAL INTERFERONS
Urgent Clinical Need for Alternative Therapy in the Resistant / Intolerant MS Group
|
| 6/1/2004 |
HEMISPHERX BIOPHARMA RECEIVES APPROVAL FOR WEST NILE VIRUS PROTOCOL WITH ALFERON N TREATMENT
Leading New York Hospital Approves Protocol
for First National Clinical Trial
|
| 5/17/2004 |
HEMISPHERX FILES EXPANDED U.S. PATENT APPLICATION FOR TREATING SARS AND EMERGING VIRUSES
Expanded Application includes Unique Oral Delivery Mechanism
|
| 5/14/2004 |
HEMISPHERX BIOPHARMA
FIRST QUARTER 2004 EARNINGS ANNOUNCED
…Cash Position Increases / GMP Manufacturing Capabilities Acquired
|
| 5/10/2004 |
HEMISPHERX BIOPHARMA LAUNCHES NEW HIV CLINICAL PROGRAM
IN AFRICA WITH COST EFFECTIVE ANTIVIRAL DELIVERY
Key Collaboration with the World Foundation Aids Research and Prevention
|
| 5/3/2004 |
HEMISPHERX BIOPHARMA ANNOUNCES PHASE 3
CHRONIC FATIGUE SYNDROME TRIAL MEETS PRIMARY ENDPOINT
Patients Receiving Ampligen Improve at Twice the Level
Considered Medically Significant
|
| 4/30/2004 |
Hemispherx Biopharma Accelerates Release Date on Phase 3 Data for Ampligen in CFS
Primary Endpoint Data for Ampligen to be Presented at 17th International Conference on Antiviral Research on May 3rd instead of May 6th
|
| 4/20/2004 |
HEMISPHERX BIOPHARMA CEO TO PRESENT AT WHITE MOUNTAIN CAPITAL BIOTECHNOLOGY CONFERENCE
Background on New Phase 3 Clinical Data on CFS to be Presented
|
| 4/19/2004 |
HEMISPHERX BIOPHARMA REPORTS PUBLICATION SHOWING
SUPERIOR ACTIVITY OF ALFERON AGAINST SARS
Alferon Highest Activity Against SARS Among 19 Clinically Approved Compounds
|
| 4/13/2004 |
Hemispherx Biopharma to Present First Phase 3 Data on Ampligen in Chronic Fatigue Syndrome at the 17th International Conference on Antiviral Research
Primary Endpoint Data Presented at International Conference to be Held May 2-6, 2004
|
| 3/18/2004 |
Hemispherx Biopharma Completes Acquisition for Worldwide Rights to Alferon N
Company Closes Final Agreement on GMP Certified Manufacturing
Facility; Expects International Sales to Begin During the Second Quarter
|
| 3/15/2004 |
HEMISPHERX BIOPHARMA REPORTS 2003 YEAR-END RESULTS
Cash Position and Total Shareholder’s Equity Increases
|
| 3/2/2004 |
HEMISPHERX BIOPHARMA ANNOUNCES FDA AUTHORIZATION
FOR A CLINICAL STUDY WITH NEW BIOLOGICAL ALFERON LDO FOR HIV
Company to Initiate Phase II Study in early-stage HIV Patients
|
| 2/25/2004 |
HEMISPHERX BIOPHARMA TO PRESENT AT
WALL STREET ANALYST FORUM ON MARCH 1st
|
| 2/18/2004 |
HEMISPHERX BIOPHARMA SIGNS OPTION AGREEMENT FOR AMPLIGEN WITH FUJISAWA PHARMACEUTICAL COMPANY
Company Receives Initial Payment in Potentially Multi Million Dollar Distribution Agreement for CFS Treatment
|
| 1/30/2004 |
HEMISPHERX BIOPHARMA FINISHES PHASE 3 CFS CLINICAL TRIAL
Completion of Placebo-Controlled Phase 3 Stage Represents Important Clinical Milestone
|
| 1/26/2004 |
HEMISPHERX BIOPHARMA REPORTS PUBLICATION SUGGESTING EFFICACY OF AMPLIGEN IN TREATING MYOCARDITIS VIRUS
Data Show Ampligen Superior to Both Recombinant and Pegelated Interferons for Life – Threatening Inflammation of the Heart
|
| 1/20/2004 |
HEMISPHERX BIOPHARMA ANNOUNCES JOINT WEST NILE VIRUS CLINICAL PROGRAM WITH NEW YORK HOSPITAL
Program, led by Nationally-recognized Infectious Disease Expert, to Test Efficacy of Alferon N as a New Drug Treatment
|
| 1/13/2004 |
Hemispherx Biopharma Announces Joint SARS Clinical Program
with Vanderbilt University
Program to Evaluate the Potential Efficacy of Alferon N in the Treatment of SARS;
New Gene Signature Diagnosis will Accelerate Therapeutic Intervention
|
| 1/8/2004 |
HEMISPHERX BIOPHARMA ACCELERATES NEW ORAL SARS PREVENTION PROGRAM
Company's Oral Interferon Could Potentially Stem Next Outbreak of Disease
|
| 1/6/2004 |
HEMISPHERX BIOPHARMA TO CONVENE LEADING SCIENTIFIC EXPERTS TO LAUNCH INNOVATIVE 2004 CLINICAL PROGRAMS
Company attracts industry experts to focus clinical activities in the areas of SARS, West Nile Virus and HIV-Prevention
|
| 12/18/2003 |
HEMISPHERX BIOPHARMA EXPANDS APPLICATIONS FOR ALFERON THROUGH NEW MANUFACTURING AGREEMENT
Manufacturing Partnership Could Give Company Ability to Deliver Alferon LDO Orally for SARS
|
| 11/20/2003 |
HEMISPHERX BIOPHARMA APPOINTS DR. ANTONIO ESTEVE
TO ITS BOARD OF DIRECTORS
Executive Committee Member of Key European Partner to Play Active Role in European Development of Alferon®
|
| 11/18/2003 |
HEMISPHERX BIOPHARMA
THIRD QUARTER EARNINGS ANNOUNCED
…Cash Position Increased and the Total Shareholders Equity Increased
|
| 11/13/2003 |
HEMISPHERX BIOPHARMA BIOTERROR PROGRAM COVERED AT FEDERAL BIODEFENSE RESEARCH FY 2004 CONFERENCE
Company’s Bioterror Treatment/Prevention Initiative Introduced in Project BioShield
|
| 11/10/2003 |
HEMISPHERX BIOPHARMA REPORTS NEW SARS DATA ON ALFERON
AT THE 14TH INTERNATIONAL ANTIVIRAL SYMPOSIUM
One of the Most Effective Antiviral Compounds Tested to Date Now Becomes Lab Standard
|
| 11/5/2003 |
HEMISPHERX BIOPHARMA TO PRESENT NEW DATA ON ALFERON IN SARS
AT IX INTERNATIONAL ANTIVIRAL SYMPOSIUM AND WORKSHOP
European Symposium To Be Held November 9-12, 2003
|
| 10/30/2003 |
HEMISPHERX BIOPHARMA COMPLETES $ 4,142,357 PRIVATE PLACEMENT
Third Multi Million Dollar Transaction in Year 2003 to
Further Expand Alferon N Sales Program and Prepare for Ampligen NDA Filing
|
| 10/29/2003 |
HEMISPHERX BIOPHARMA APPOINTS DR. LUC MONTAGNIER,
LEADING HIV EXPERT, TO SERVE ON SCIENTIFIC ADVISORY BOARD
Growing Recognition for Potential of Ampligen attracts Discoverer of HIV/AIDS Virus & Pioneer in Disease Treatment and Prevention
|
| 10/23/2003 |
HEMISPHERX BIOPHARMA APPOINTS PROFESSOR JAMES J. RAHAL, M.D.,
WEST NILE VIRUS EXPERT, TO SCIENTIFIC ADVISORY BOARD
Clinical Expertise in New Biodefense and Emerging Infectious Disease Area
|
| 10/21/2003 |
HEMISPHERX BIOPHARMA APPOINTS JACK M. GWALTNEY JR., M.D. TO SCIENTIFIC ADVISORY BOARD
International Expert on Topical Delivery of Broad-Spectrum Antivirals to Protect Large, at Risk, Populations
|
| 10/16/2003 |
HEMISPHERX BIOPHARMA APPOINTS ANTHONY KOMAROFF, M.D.,
HARVARD UNIVERSITY PROFESSOR AND LEADING CFS EXPERT
TO SCIENTIFIC ADVISORY BOARD
|
| 10/14/2003 |
HEMISPHERX BIOPHARMA EXPANDS SARS PREVENTION/TREATMENT INITIATIVE
Prior to Anticipated Fall/Winter Outbreak also widens Distribution and Clinical Networks
|
| 9/15/2003 |
HEMISPHERX BIOPHARMA REPORTS ON ANNUAL MEETING
.…Capital Structure Doubles and Company reconfirms its Year 2003 Targets
…. Present Management Re-elected by Large Majority
|
| 9/4/2003 |
HEMISPHERX BIOPHARMA SIGNS AGREEMENT WITH GUANGDONG MEDICINE GROUP CORPORATION
Partnership for Clinical Program, Sales and Distribution in the People’s Republic of China for the Treatment of HCV and HIV
|
| 8/20/2003 |
HEMISPHERX BIOPHARMA SECOND QUARTER EARNINGS ANNOUNCED
Cash Position Increased and the Total Shareholders Equity Improved
|
| 8/18/2003 |
HEMISPHERX BIOPHARMA ENTERS INTO SALES AND MARKETING AGREEMENT WITH ENGITECH FOR ALFERON N
Agreement Provides Nationwide Sales Team for Alferon N
|
| 8/11/2003 |
HEMISPHERX BIOPHARMA ENTERS INTO AGREEMENT WITH THE JOHANN WOLFGANG GOETHE UNIVERSITY, INSTITUTE OF VIROLOGY
Independent US Scientific Panel Recommends Further Evaluation of Ampligen® for SARS
|
| 8/4/2003 |
HEMISPHERX BIOPHARMA RECEIVES NEW PATENTS FOR ORAL DOSED
BROAD-SPECTRUM IMMUNE ACTIVATORS
Company Prepares Applications to Bioterror and Emerging Infectious Diseases Granting Programs
|
| 7/29/2003 |
HEMISPHERX REPORTS AMPLIGEN PREVENTS DESTRUCTION OF NERVE CELLS
AND INCREASES SURVIVAL RATES IN FLAVIVIRUS INFECTION
Independent Study shows Ampligen® demonstrates Broad-Based Potential in Virus Classes associated with Bioterror and West Nile Virus
|
| 7/15/2003 |
HEMISPHERX REPORTS NEW HIV TREATMENT DATA ON AMPLIGEN
AT THE 2nd IAS CONFERENCE ON HIV PATHOGENESIS AND TREATMENT
Initial Therapeutic Data on Immune Response Now Confirmed
over Significantly Longer Observation Period
|
| 7/11/2003 |
HEMISPHERX COMPLETES $ 5,500,000 PRIVATE PLACEMENT
Second $ 5.5 Million Transaction in 4 Months to Accelerate Market Development and Additional Commercial Approvals
|
| 6/30/2003 |
HEMISPHERX NET ASSETS RISE BY $ 2.8 MILLION
Shareholder Equity increases over Previous Reporting Quarter
|
| 6/23/2003 |
HEMISPHERX BIOPHARMA ANNOUNCES INDEPENDENT STUDY THAT SHOWS AMPLIGEN® SUPERIOR TO OTHER ANTIVIRALS
Prof. Neyts receives prestigious Prusoff Award for research potentially applicable to SARS
|
| 6/19/2003 |
HEMISPHERX ENTERS AGREEMENT WITH BUSINESS ASIA CONSULTANTS
An American/Chinese Cooperative Agreement to Accelerate SARS program
|
| 6/17/2003 |
HEMISPHERX SIGNS LETTER OF INTENT WITH GUANGDONG MEDICINE CO.
A Chinese Collaboration Partner for SARS Program
|
| 6/2/2003 |
HEMISPHERX REPORTS DATA ON ALFERON AT SARS CONFERENCE
Clinical Study of Relative Safety Profiles of Natural IFN over Recombinant IFN suggests less Drug Induced Morbidity
|
| 5/29/2003 |
HEMISPHERX PARTICIPATES IN ANTI-SARS FORUM
Hemispherx Gives Keynote Speech at “Anti-SARS Forum”
Organized by Sino-American Pharmaceutical Association
|
| 5/27/2003 |
HEMISPHERX FILED PATENT APPLICATIONS TO COMBAT SARS
Hemispherx Confirms Filing Patent Applications for the Use of Alferon N Injection® and Ampligen® for treating SARS
|
| 5/21/2003 |
SARS: Newly NIH Sponsored Studies of Potential Therapies for SARS now Finds Hemispherx’ Ampligen® among the Most Active from a Large Pool of 70 (Seventy) Drug Candidates
|
| 5/21/2003 |
Hemispherx Announces Acceleration of Manufacturing Process of Alferon N
Higher Product Demand Anticipated in View of Increased Incidence of HPV
Reported by Federal Agencies
|
| 5/20/2003 |
HEMISPHERX ANNOUNCES FIRST QUARTER RESULTS
…..Overall Operating Expenses Decrease 22% Over Prior Year.
…..Fully Commercialized Immune-Based Antiviral Product Acquired.
|
| 5/19/2003 |
Hemispherx Reports Positive Independent Study Results of Alferon N in the Treatment of Pig Coronavirus (Animal Model of SARS)
Amsterdam Group proves Koch’s Postulates on Human Coronavirus (SARS)
Clinical Study Shows Significantly Greater Survival Rates of Treated Piglets in Natural Outbreaks
Low Dose Alferon N Effective within 4 days of Treatment
|
| 5/13/2003 |
Hemispherx Initiates Collaboration on SARS with Genome Institute of Singapore
Company launches efforts to combat SARS with its lead Products Ampligen® and Alferon® N
|
| 5/8/2003 |
Hemispherx Biopharma: New NIH Sponsored Data on Ampligen presented
with West Nile Virus
Ampligen effective in reducing morbidity and mortality in two different animal studies
New FDA Regulations may permit accelerated commercialization
|
| 5/5/2003 |
HEMISPHERX BIOPHARMA ENTERS INTO THERAPEUTIC AGREEMENT FOR AMPLIGEN® WITH THE CENTER FOR CELL AND GENE THERAPY AT BAYLOR COLLEGE OF MEDICINE
Immune stimulation through dendritic cells holds promise for increasing cancer remission rates.
|
| 4/29/2003 |
HEMISPHERX REPORTS EXPANDED HIV DATA ON AMPLIGEN AT THE 16th INTERNATIONAL CONFERENCE ON ANTIVIRAL RESEARCH
Mean Duration of S.T.I. with Ampligen is 25+ weeks vs. 13 weeks for the Control Group.
Increase in CD8+ cells in the Ampligen arm also observed.
|
| 4/22/2003 |
HEMISPHERX BIOPHARMA EXTENDS DISTRIBUTOR AGREEMENT
FOR ALFERON N Injection
- - - -
National Institute of Health reports 5.5 Million new genital Human Pamplona Virus outbreaks each year
Center of Disease Control reports related Sexually Transmitted Diseases healthcare costs second only to HIV
|
| 4/15/2003 |
Hemispherx Biopharma Announces Fourth Quarter and Year 2002 Results
Cash and Equivalents Increased 6.0 Million Dollars by Recent Transactions
G&A and Cash Loss Reduced
Phase III CFS Clinical Trials Targeted for Completion in 2003
Commercial Expansion of Fully Natural Interferon Proceeding on Target
|
| 4/8/2003 |
Webcast Alert:
Hemispherx BioPharma, Inc. Announces HEB Presentation at Redchip Partners New York Investor Conference 2003 Webcast
|
| 3/26/2003 |
HEMISPHERX BIOPHARMA APPOINTS DAVID FEDORCZYK
DIRECTOR OF CLINICAL AND STATISTICAL AFFAIRS
- - - -
History Of Successful Record In FDA Commercial Filings
|
| 3/24/2003 |
HEMISPHERX BIOPHARMA APPOINTS DR. JAMES KNILL
VICE PRESIDENT OF CLINICAL DEVELOPMENT OF THE HIV/AIDS DIVISION
- - - - -
Former High Ranking VP At Squibb Dr. Knill Has Long Track Record Of
Successful Completion Of Trials For Large Volume Drugs
|
| 3/20/2003 |
HEMISPHERX BIOPHARMA TO PRESENT AT THE
STRATEGIC RESEARHC INTSTITUTES
FIRST ‘siRNA’ CONFERENCE
- - - - -
Conference To Be Held March 24-25, 2003
At Hilton La Jolla, California
|
| 3/18/2003 |
REBROADCAST OF HEMISPHERX’S MARCH 18, 2003
CONFERENCE CALL AVAILABLE ON COMPANY’S
WEBSITE OR VIA TELEPHONE REPLAY
|
| 3/13/2003 |
HEMISPHERX TO HOST CONFERENCE CALL ON TUESDAY, MARCH 18, 2003 AT 11:00AM EST
Call to focus on Recent Acquisition, Funding and Forward Commercialization Strategies
|
| 3/12/2003 |
HEMISPHERX ACQUIRES RIGHTS FOR THE ONLY FDA APPROVED NATURAL ALPHA INTERFERON DRUG Company Completes a $5,500,000 Private Placement Conference Call to be Held On Tuesday, March 18, 2003 at 11:00am EST
|
| 3/6/2003 |
Hemispherx Biopharma to Present New Interim Clinical Data Regarding Phase IIB Study in HIV/AIDS at the 16th International Conference on Antiviral Research
|
| 2/12/2003 |
Expanded Clinical Data on AmpligenÒ in HIV Disease to be presented at the 16th International Conference on Antiviral Research
Phase II B Study Evaluates Experimental Immunotherapy in “Holiday” Period when Antiviral Cocktails are Discontinued
|
| 1/31/2003 |
Hemispherx Presents New Data on Long-term, Post-trial Effects of RNA-based Ampligen(R) for Treatment for Chronic Fatigue Syndrome
At Sixth Annual American Association of Chronic Fatigue Syndrome Conference January 31 - February 2, Chantilly, Virginia
|
| 1/24/2003 |
HEMISPHERX ANNOUNCES TAGLICH BROTHERS RELEASE OF UPDATED RESEARCH REPORT
|
| 1/22/2003 |
REBROADCAST
OF HEMISPHERX’S JANUARY 21, 2003 CONFERENCE CALL AVAILABLE ON COMPANY’S WEBSITE OR VIA TELEPHONE REPLAY
|
| 1/17/2003 |
HEMISPHERX SCHEDULES CONFERENCE CALL TO REVIEW RECENT DEVELOPMENTS IN CLINICAL TRIAL EXPANSION, STRATEGIC PARTNERSHIP SUPPORT, FUNDING AND THE OVERALL COMMERCIALIZATION PROCESS
|
| 1/15/2003 |
Hemispherx Biopharma’s International Team of Clinical Researchers to Present New Data on Experimental Treatment of CFS
“Expanded Access” Program with Ampligen® Includes 10 Treatment Centers in USA
|
| 1/15/2003 |
HEMISPHERX FILES WITH REGULATORS TO REGISTER 5 MILLION SHARES OF STOCK TO SUPPORT CLINICAL TRIAL EXPANSION
|
| 1/15/2003 |
OFFUTT SECURITIES UPDATES INDEPENDENT RESEARCH COVERAGE ON HEMISPHERX BIOPHARMA, INC.
|
| 12/18/2002 |
Rebroadcast of Hemispherx's December 18, 2002 Conference Call Available On Company’s Website or Via Telephone Replay
|
| 12/17/2002 |
Hemispherx to Host Conference Call on Recent Presentation at the
2002 DART Conference and Other Recent Developments
Call Scheduled for Wednesday, December 18, 2002 at 11:00 AM Eastern Standard Time
|
| 12/17/2002 |
Hemispherx Presents New Data from Phase IIB Clinical Trial of RNA-based Ampligen® for Structured Treatment Interruption in HIV at DART Conference
Ampligen® Study Indicates Prolonged Time Off AIDS Drugs Without Viral Rebound
|
| 12/16/2002 |
Hemispherx Files New US Patent Application on Immune-Based
Alternative Treatment to HIV/AIDS
Designed to protect ‘sanctuary’ regions of the body where virus
hides and mutates into drug resistant strains.
|
| 12/9/2002 |
HEMISPHERX BIOPHARMA COMPLETES FULL ENROLLMENT OF ITS PHASE III CLINICAL TRIAL FOR CHRONIC FATIGUE SYNDROME (CFS)
First Ever Completely Enrolled Phase III Clinical Trial for Disorder Affecting Over 500,000 Americans Surpasses Enrollment Target; Data Analysis Expected in 2003.
|
| 11/25/2002 |
Hemispherx Biopharma Invited to Present New Anti HIV Data at DART Conference: Phase IIB Clinical Trials of Strategic Treatment Intervention
Major Drug Development in Antiretroviral Research (DART) Conference 2002 in Naples, Florida, Tuesday, December 17
|
| 11/20/2002 |
Hemispherx Biopharma, Inc. Adopts Stockholder Rights Plan
|
| 11/18/2002 |
Hemispherx Biopharma and Sigma-Aldrich Enter Agreement to Produce Hemispherx’s RNA-based Ampligen® in U.S.
|
| 11/15/2002 |
Hemispherx Announces Third Quarter Results
Four Robust Advance-Stage Clinical Programs Accelerate as Revenues Increase.
-----
Cash And Cash Equivalents Increased over Prior Nine Month Period
|
| 11/4/2002 |
Hemispherx Biopharma RNA Drug Technology Targets New Molecular Defects Uncovered in Prostate Cancer
National Human Genome Research Pinpoints First Specific Gene Which Confers High Risk for Prostate Cancer
Prostate 'Cancer Susceptibility Gene' is New Therapeutic Target
|
| 10/21/2002 |
HEMISPHERX BIOPHARMA PROFILED ON TOP10MICROCAPSTOCKS.COM
Website Focuses on Analysis and Tracking Micro Cap Companies in Various Industries
|
| 10/9/2002 |
HEMISPHERX BIOPHARMA RNA DRUG TECHNOLOGY PIPELINE SHOWS THERAPEUTIC PROMISE IN U.S. GOVERNMENT SPONSORED RESEARCH
Specific New Inhibitory Effects Demonstrated on Bioterror–type Agents
|
| 9/3/2002 |
Hemispherx Biopharma Will Be Presenting at The Wall Street Analyst Forum in New York on September 9, 2002
|
| 8/19/2002 |
Hemispherx Biopharma Receives Letter of Intent for Potential Multimillion-dollar Investment by Royal Family of United Arab Emirates
Understanding Announced at Annual Meeting in Philadelphia
Global Technology Expands as Company-held Patents Approach the 400 Mark
Clinical Trial for HIV and Hepatitis C Set to Start in Spain
|
| 8/15/2002 |
HEMISPHERX ANNOUNCES SECOND QUARTER RESULTS
Cash and Cash Equivalents Up 22%
-
Operating Losses Reduced By Over 15%
-
Three Major Clinical Trails Expanded
|
| 7/30/2002 |
HEMISPHERX ANNOUNCES DETAILS ON WALL STREET REPORTER ROUNDTABLE SCHEDULED FOR WEDNESDAY JULY 31ST AT 2 PM EST
Critical Scientific And Investment Related Issues In The Biotech Sector Will Be Discussed By A Panel Of Peers
|
| 7/25/2002 |
HEMISPHERX ANNOUNCES CONFERENCE CALENDAR
Hemispherx Biopharma to Present at Several Scientific and Financial Conferences
|
| 7/11/2002 |
HEMISPHERX SCHEDULES CONFERENCE CALL TO REVIEW NEW DATA PRESENTED AT THE INTERNATIONAL AIDS CONFERENCE IN BARCELONA.
|
| 7/11/2002 |
HEMISPHERX REPORTS AMPLIGEN DATA DEMONSTRATING A MEDIAN HAART-FREE (STI) INTERVAL OF 25+ WEEKS AT INTERNATIONAL AIDS CONFERENCE IN BARCELONA
Median Duration of Strategic Treatment Intervention (STI) with Ampligen is 25+ weeks vs. 7 weeks for the control group.
|
| 7/11/2002 |
HEMISPHERX REPORTS NEW AMPLIGEN DATA DEMONSTRATING A MEDIAN 0.5 LOG DROP IN VIRAL LOAD AT INTERNATIONAL AIDS CONFERENCE IN BARCELONA
Ampligen as an adjunct to HAART decreases HIV RNA levels by 0.50 Log after a median duration of 4.5 months.
|
| 7/1/2002 |
Hemispherx Announces Annual Shareholders Meeting To Be Held August 14th, 2002
|
| 6/18/2002 |
HEMISPHERX BIOPHARMA RECEIVES NOTIFICATION OF ACCEPTANCE OF ITS TWO LATE BREAKER ABSTRACTS FOR THE XIV INTERNATIONAL AIDS CONFERENCE.
Abstracts cover latest developments in the Company’s HIV/AIDS Clinical Trials for Salvage Therapy and Strategic Treatment Intervention (STI)
|
| 6/10/2002 |
Hemispherx Biopharma Receives New Patent In Europe For Oral Dosed Broad-Spectrum Immune Activators
|
| 6/5/2002 |
Hemispherx Biopharma Europe S.A. Completes Agreement With Laboratorios Del Dr. Esteve S.A.
Cash Infusion, Distribution, and Clinical Trials Provided in Accord
|
| 5/16/2002 |
AUDIO WEB REPLAY OF HEMISPHERX’S MAY 16, 2002 CONFERENCE CALL AVAILABLE ON COMPANY’S WEBSITE
|
| 5/15/2002 |
HEMISPHERX ANNOUNCES FIRST QUARTER RESULTS
REVENUE INCREASED-NET LOSS REDUCED BY 40%
New Strategic Partnership in Europe is Disclosed
|
| 5/15/2002 |
HEMISPHERX TO HOST CONFERENCE CALL ON FIRST QUARTER RESULTS AND NEW HIV/AIDS ACTIVITY
Call Scheduled For Thursday, May 16, 2002 At 10:30 AM
|
| 5/1/2002 |
PRESIDENT/OWNER OF MAJOR INTERNATIONAL OIL EXPLORATION COMPANIES JOINS HEMISPHERX BIOPHARMA BOARD OF DIRECTORS
------
Dr. Kiani Expands Commitment Of Intellectual And Financial Resource In Field Of Clinical Immunology After Spectacular Career in Global Oil and Gas Development Projects
|
| 4/29/2002 |
Hemispherx Announces Formation of Committee to Initiate Search
For Medical Director to Lead its HIV/AIDS Division
Clinical Results To Date Accelerate Patient Accrual and Expand Programs
|
| 4/18/2002 |
Hemispherx and The AIDS Community Research Initiative of America -- ACRIA -- Launch Immunotherapeutic HIV/AIDS Clinical Trials in New York City
Trials Will Explore Use Of Ampligen® In Both ``Salvage'' And ``Strategic Interruption'' Studies
|
| 4/8/2002 |
Hemispherx Announces Fourth Quarter and Full Year Results
Cash And Equivalents Increased To 8.4 Million Dollars G&A And Cash Loss Reduced
|
| 4/4/2002 |
Hemispherx to Present Today At 1:30 PM On the American Stock Exchange Invitation On Line Conference
Company Will Discuss Recent Result of HIV/AIDS Clinical Trials as Presented At Medical Conference Held in Prague, Czech Republic
|
| 3/26/2002 |
Hemispherx Biopharma Launches New Website
|
| 3/19/2002 |
Hemispherx Disseminates New Clinical Data on Experimental Treatment of Multi-Drug Resistant HIV/AIDS Virus
Virus Levels Observed to Drop
|
| 3/18/2002 |
Hemispherx Announces Poly I:Poly C12U Increases the Control of HIV During Strategic Treatment Interruption in Chronically HIV Infected Patients
Ampligen® Increases the Length of Time Before Viral ``Rebound'' Occurs
|
| 2/27/2002 |
Hemispherx to Present New Clinical Data on Experimental Treatment of Multi-Resistant HIV/AIDS Virus
New Mechanism of Immunosurveillance Being Tested Clinically
|
| 2/22/2002 |
Hemispherx Defamation Trial Results in Claims of Both Parties Being Denied
Jury Fails To Award Damages Against Asensio;
Asensio's Counterclaims Withdrawn, Unable To Be Reintroduced
|
| 1/28/2002 |
Hemispherx Continues To Enroll New Clinical Investigators
And Expand Clinical Trial Sites In HIV Trials
Company Also Prepares To Present At Upcoming Scientific Conferences
|
| 12/4/2001 |
Hemispherx Comments on New Report From U.S. Agency for Healthcare Research and Quality -- AHRQ -- on Chronic Fatique
Syndrome -- CFS --
CFS Is Recognized, Defined, and Number of Sufferers Are Estimated
Phase III Level Ampligen® Yielded the Most Promising Results of All Therapies Surveyed
|
| 11/14/2001 |
HEMISPHERx ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
-----
Public Warrant Conversions Boost Net Worth
|
| 11/1/2001 |
Hemispherx Biopharma Will Announce New HIV Clinical Treatment Data On Immune Intervention during “Drug Holidays” at WHO Conference
|
| 10/17/2001 |
Hemispherx Awarded U.S. Patent on Novel Fusion Inhibitor of HIV
|
| 10/4/2001 |
HEMISPHERX REPORTS ON PROGRESS IN EUROPE -- Steady Organizational Growth Since February 2000 Prepares Company For European Trials And Product Introduction
|
| 10/2/2001 |
Hemispherx Scientists Report New Method To Evaluate Chronic Fatigue Syndrome
|
| 10/2/2001 |
Hemispherx Biopharma Announces Notice Of Warrant Expiration Date
|
| 7/24/2001 |
HEMISPHERX BIOPHARMA SELECTED BY MSN MONEY CENTRAL’S STOCKSCOUTER AS ONE OF HIGHEST RATED SMALL-CAP BIOTECHS
|
| 6/25/2001 |
HEMISPHERX BIOPHARMA SPONSORS GLOBAL AIDS FUNDRAISER AT UNITED NATIONS
|
| 6/14/2001 |
HEMISPHERX BIOPHARMA INITIATES TREATMENT IN TWO NEW CLINICAL STUDIES OF MULTI-DRUG RESISTANT HIV-INFECTION IN U.S.A.--Culminates 15 Year Period of Discoveries-
|
| 5/9/2001 |
Hemispherx Biopharma, LabCorp® combine forces for Nationwide testing in HIV Immunotherapy Clinical Trials
|
